Save Recarbrio as a Last Resort for Resistant Infections

February 2020

Recarbrio (reh-CAR-bree-oh, imipenem/cilastatin/relebactam) is a new combo antibiotic for resistant gram-negative infections.

It follows in the footsteps of other novel, broad-spectrum beta-lactamase inhibitor combos...such as Vabomere (meropenem/vaborbactam) and Avycaz (ceftazidime/avibactam).

Relebactam is a beta-lactamase inhibitor that restores imipenem's activity against organisms, such as resistant Pseudomonas or common carbapenem-resistant Enterobacteriaceae (CRE).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote